Ichiro Kawada

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Investigational new drugs

JGH open : an open access journal of gastroenterology and hepatology

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Masahiko Okada, Noriyuki Ishida, Sho Kanzaki, Ichiro Kawada, Kengo Nagashima, Hideki Terai, Gaku Hiruma, Ho Namkoong, Takanori Asakura, Katsunori Masaki, Keiko Ohgino, Jun Miyata, Shotaro Chubachi, Nobuhiro Kodama, Shunsuke Maeda, Satoshi Sakamoto, Masaki Okamoto, Yoji Nagasaki, Akira Umeda, Kazuya Miyagawa, Hisato Shimada, Kazuhiro Minami, Rie Hagiwara, Makoto Ishii, Yasunori Sato, Koichi Fukunaga
Upper Respiratory Symptoms as Long COVID: Insight from a Multicenter Cohort Study. OTO open 8 (1) (2024)
Masahiko Okada, Noriyuki Ishida, Sho Kanzaki, Ichiro Kawada, Kengo Nagashima, Hideki Terai, Gaku Hiruma, Ho Namkoong, Takanori Asakura, Katsunori Masaki, Keiko Ohgino, Jun Miyata, Shotaro Chubachi, Nobuhiro Kodama, Shunsuke Maeda, Satoshi Sakamoto, Masaki Okamoto, Yoji Nagasaki, Akira Umeda, Kazuya Miyagawa, Hisato Shimada, Kazuhiro Minami, Rie Hagiwara, Makoto Ishii, Yasunori Sato, Koichi Fukunaga
Upper Respiratory Symptoms as Long COVID: Insight from a Multicenter Cohort Study. OTO open 8 (1) (2024)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Kazuma Yagi, Takanori Asakura, Hideki Terai, Keiko Ohgino, Katsunori Masaki, Ho Namkoong, Shotaro Chubachi, Jun Miyata, Ichiro Kawada, Nobuhiro Kodama, Satoshi Sakamoto, Akira Umeda, Takashi Ishiguro, Makoto Ishii, Koichi Fukunaga
Clinical features of Japanese patients with gastrointestinal long-COVID symptoms. JGH open : an open access journal of gastroenterology and hepatology 7 (12) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Kazuma Yagi, Takanori Asakura, Hideki Terai, Keiko Ohgino, Katsunori Masaki, Ho Namkoong, Shotaro Chubachi, Jun Miyata, Ichiro Kawada, Nobuhiro Kodama, Satoshi Sakamoto, Akira Umeda, Takashi Ishiguro, Makoto Ishii, Koichi Fukunaga
Clinical features of Japanese patients with gastrointestinal long-COVID symptoms. JGH open : an open access journal of gastroenterology and hepatology 7 (12) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Naofumi Kameyama, Takashi Sato, Daisuke Arai, Daisuke Fujisawa, Mari Takeuchi, Ichiro Nakachi, Ichiro Kawada, Hiroyuki Yasuda, Shinnosuke Ikemura, Hideki Terai, Shigenari Nukaga, Yasushi Nakano, Toshiyuki Hirano, Naoto Minematsu, Takanori Asakura, Takashi Kamatani, Kyuto Tanaka, Shoji Suzuki, Masayoshi Miyawaki, Katsuhiko Naoki, Koichi Fukunaga, Kenzo Soejima
Most Important Things and Associated Factors With Prioritizing Daily Life in Patients With Advanced Lung Cancer. JCO oncology practice (2022)
Katsunori Masaki, Shigeharu Ueki, Keiji Tanese, Genta Nagao, Sho Kanzaki, Eri Matsuki, Hidehiro Irie, Hiroki Kabata, Jun Miyata, Ichiro Kawada, Koichi Fukunaga
Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab. Asia Pacific allergy 11 (3) (2021)